Mills Peninsula Medical Center

Sutter Health

Cerebral Hemorrhage

Hemorrhage

Hemorrhagic Stroke

Joseph Broderick, MD

condition

allSponsorName

National Institutes of Health (NIH)

Novo Nordisk

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

The objective of the rFVIIa for Acute Hemorrhagic Stroke Administered at Earliest Time (FASTEST) Trial is to establish the first treatment for acute spontaneous intracerebral hemorrhage (ICH) within a time window and subgroup of patients that is most likely to benefit. The central hypothesis is that rFVIIa, administered within 120 minutes from stroke onset with an identified subgroup of patients most likely to benefit, will improve outcomes at 180 days as measured by the Modified Rankin Score (mRS) and decrease ongoing bleeding as compared to standard therapy.

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial

Sutter Health | Mills Peninsula Medical Center

Site insights

Work at this site?

Active trials

Recombinant Factor VIIa (rFVIIa) for Hemorrhagic Stroke Trial (FASTEST)

Trial sponsors